InvestorsHub Logo
Followers 55
Posts 6417
Boards Moderated 1
Alias Born 07/28/2015

Re: None

Tuesday, 10/11/2022 3:41:49 PM

Tuesday, October 11, 2022 3:41:49 PM

Post# of 113754
Both AEGIS & SBFM requested acceleration and were denied. Interesting, I did not know Steve requested twice, as well as AEGIS. They did not get approval or acceleration.

AEGIS's acceleration request:

https://fintel.io/doc/sec-sunshine-biopharma-inc-1402328-corresp-2022-february-09-19067-6279

Steve Slilaty's acceleration request to the SEC:

https://fintel.io/doc/sec-sunshine-biopharma-inc-1402328-corresp-2022-february-09-19067-2687

Again here:

https://fintel.io/doc/sec-sunshine-biopharma-inc-1402328-corresp-2022-april-07-19119-3528

From 5/10/22:
"Investing in our common stock involves substantial risk. Please read ?Risk Factors? beginning on page 4 of this prospectus and in the documents we incorporate by reference.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
"

https://fintel.io/doc/sec-sunshine-biopharma-inc-1402328-s3-2022-may-10-19123-6630

SEC's denial and refusal to review the two Steve Slilaty acceleration requests as well as AEGIS.

United States securities and exchange commission logo
May 18, 2022
Steve Slilaty
Chief Executive Officer
Sunshine Biopharma, Inc
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
Re: Sunshine Biopharma, Inc
Registration Statement on Form S-3
Filed May 10, 2022
File No. 333-264830
Dear Dr. Slilaty:
This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alyssa Wall at 202-551-8106 with any questions.

Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Jeff Cahlon

Link: https://www.sec.gov/Archives/edgar/data/1402328/000000000022005515/filename1.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News